Victor C Shi Selected Research

Angiotensin Receptors (Angiotensin II Receptor)

1/2021	Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction.
10/2019	Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
1/2018	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.
8/2017	Health-Related Quality of Life Outcomes in PARADIGM-HF.
1/2017	Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.
1/2017	Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction.
1/2017	Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial.
1/2017	Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
12/2016	Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.
6/2016	Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF).

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Victor C Shi Research Topics

Disease

36	Heart Failure 08/2021 - 09/2013
6	Cardiomyopathies (Cardiomyopathy) 01/2021 - 01/2018
4	Hypotension (Low Blood Pressure) 10/2019 - 09/2014
3	Heart Diseases (Heart Disease) 10/2019 - 01/2017
2	Diabetes Mellitus 01/2021 - 01/2016
2	Hyperkalemia 10/2019 - 09/2014
2	Angioedema 10/2019 - 09/2014
1	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 08/2021
1	Bundle-Branch Block (Fascicular Block) 08/2021
1	Neoplasms (Cancer) 08/2021
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2021
1	Obesity 01/2020
1	Coronary Disease (Coronary Heart Disease) 01/2020
1	Edema (Dropsy) 10/2019
1	Dyspnea (Shortness of Breath) 10/2019
1	Paroxysmal Dyspnea (Paroxysmal Nocturnal Dyspnea) 10/2019
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2018
1	Chronic Renal Insufficiency 01/2018
1	Myocardial Infarction 06/2017
1	Stroke (Strokes) 06/2017
1	Sudden Death 06/2017
1	Insulin Resistance 01/2017
1	Cognitive Dysfunction 01/2017
1	Dementia (Dementias) 01/2017
1	Disease Progression 01/2015
1	Cough 09/2014
1	Left Ventricular Dysfunction 07/2014
1	Systolic Heart Failure 09/2013
1	Arteriosclerosis 01/2006

Drug/Important Bio-Agent (IBA)

27	sacubitril and valsartan sodium hydrate drug combinationIBA 08/2021 - 07/2014
18	Neprilysin (Neutral Endopeptidase)IBA 01/2021 - 09/2013
16	Angiotensin Receptors (Angiotensin II Receptor)IBA 01/2021 - 09/2013
15	Enalapril FDA LinkGeneric 08/2021 - 07/2014
11	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2021 - 01/2015
8	paragonIBA 01/2021 - 01/2017
7	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2021 - 11/2016
6	pro-brain natriuretic peptide (1-76)IBA 01/2021 - 09/2013
5	Natriuretic PeptidesIBA 10/2019 - 07/2014
4	Valsartan (Vals)FDA Link 01/2020 - 01/2017
4	AngiotensinsIBA 10/2019 - 09/2014
4	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 01/2017 - 09/2013
3	Angiotensin Receptor AntagonistsIBA 01/2021 - 01/2018
3	DiureticsIBA 01/2021 - 01/2018
2	Uric Acid (Urate)IBA 11/2020 - 01/2018
2	Biomarkers (Surrogate Marker)IBA 11/2020 - 01/2020
2	Pharmaceutical PreparationsIBA 01/2017 - 07/2014
1	aliskiren FDA Link 08/2021
1	ChloridesIBA 08/2021
1	CreatinineIBA 08/2021
1	Serum AlbuminIBA 08/2021
1	LipidsIBA 01/2021
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2021
1	PotassiumIBA 01/2021
1	sacubitrilIBA 10/2019
1	Peptides (Polypeptides)IBA 01/2017
1	EnzymesIBA 01/2017
1	Hemoglobins (Hemoglobin)IBA 01/2016
1	Eplerenone (Inspra)FDA LinkGeneric 11/2015

Therapy/Procedure

9	Therapeutics 01/2021 - 07/2014
1	Patient Readmission 01/2020
1	Drug Tapering 01/2017
1	Critical Care (Surgical Intensive Care) 01/2015
1	Heart Transplantation (Grafting, Heart) 01/2015
1	Organ Transplantation 01/2006